HHS Federal Drug Testing Panel
The HHS federal drug test screens for five specific drug classes: marijuana (THC), cocaine, phencyclidine (PCP), opiates (with focus on heroin metabolites), and amphetamines (including MDMA, MDEA, and MDA). 1
Standard Five-Panel Testing
The Mandatory Guidelines for Federal Workplace Drug Testing Programs, established following the Drug-Free Workplace Act of 1988, specifically and exclusively focus on these five drug classes 1. This standardized panel has remained consistent through multiple revisions (1994,1998, and 2004) by the Substance Abuse and Mental Health Services Administration 2.
What This Means Clinically:
- Marijuana: Detects THC metabolites
- Cocaine: Detects cocaine metabolites
- Phencyclidine (PCP): Detects PCP
- Opiates: Specifically focuses on heroin metabolites (not all opioids)
- Amphetamines: Includes methamphetamine and designer drugs like MDMA (Ecstasy), MDEA, and MDA 2
Critical Limitations to Understand
Drugs NOT Included in Standard HHS Testing:
The standard federal panel has significant gaps that clinicians must recognize:
- Benzodiazepines: Not part of the federal mandate 3
- Synthetic cannabinoids ("spice"): Not detected 3
- Most prescription opioids: The opiate panel focuses on heroin metabolites and may miss many commonly prescribed opioids 1
- Newer designer drugs: Not included unless specifically added 3
Important Testing Nuances:
For opiates: The federal panel targets heroin metabolites specifically, which means many prescription opioids may not trigger a positive result despite being in the same drug class 1.
For amphetamines: Methylphenidate (Ritalin, Concerta) is NOT detected on routine amphetamine panels, so a positive amphetamine result cannot be explained by methylphenidate use 3.
For benzodiazepines (when added to panels): Most screens identify oxazepam and will miss commonly misused drugs like clonazepam, which has different metabolism 3.
Future Expansion Considerations
HHS has proposed expanding testing capabilities to include alternative specimen types (hair, oral fluid, sweat patches) and point-of-collection testing devices, but these remain supplementary to the core five-drug urine panel 2. These alternative matrices may be useful in specific contexts: hair for detecting chronic use up to 90 days, oral fluid for recent use within hours, and sweat patches for monitoring treatment programs 2.